Johnson & Johnson's pharmaceutical unit remains on track to drive above-market compound annual growth through 2021, even without one of the new drugs the diversified pharma had hoped to have on the market, Worldwide Chairman-Pharmaceuticals Joaquin Duato assured investors during the company's third quarter sales and earnings call Oct. 17.
J&J announced in its quarterly release that it would withdraw global regulatory filings for the interleukin-6 inhibitor sirukumab for rheumatoid...








